{"id":9877,"date":"2023-05-17T08:10:14","date_gmt":"2023-05-17T12:10:14","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/johnson-johnson-or-eliquis-maker\/"},"modified":"2023-05-17T08:10:15","modified_gmt":"2023-05-17T12:10:15","slug":"johnson-johnson-or-eliquis-maker","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=9877","title":{"rendered":"Johnson &#038; Johnson Or Eliquis\u2019 Maker?"},"content":{"rendered":"<div>\n<p>We believe <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/\">Bristol Myers Squibb stock (NYSE: BMY)<\/strong> is a better pick than its industry peer, <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/JNJ\/\">Johnson &amp; Johnson (NYSE: JNJ)<\/strong>. J&amp;J trades at a higher valuation of <strong>4.4x<\/strong> trailing revenues, compared to <strong>3.1x<\/strong> for BMS, and this valuation gap will likely narrow over the coming years in favor of BMS, in our view. While BMS has seen better revenue growth in recent years, J&amp;J is more profitable and has a better financial position, as discussed below.<\/p>\n<p>Looking at stock returns, BMY has fared slightly better with -5% returns this year vs. -10% returns for JNJ. However, both have underperformed the broader S&amp;P500 index, up 8%. There is more to the comparison, and in the sections below, we discuss why we believe BMY stock will offer higher returns than JNJ stock in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/JNJ\/no-login-required\/snZKa0ew\/Johnson-Johnson-vs-Bristol-Myers-Squibb-With-Return-Forecast-Of-44-Bristol-Myers-Squibb-Is-A-Better-Bet?fromforbesandarticle=trefis230516\">Johnson &amp; Johnson vs. Bristol Myers Squibb<\/strong><fbs-ticker data-name=\"BMY\" data-href=\"https:\/\/www.forbes.com\/companies\/bristol-myers-squibb\" data-type=\"stock\"><br \/>\n  BMY<br \/>\n <\/fbs-ticker>: <strong>Which Stock Is A Better Bet?<\/strong> Parts of the analysis are summarized below.<\/p>\n<p><strong>1. BMS\u2019 Revenue Growth Is Better<\/strong><\/p>\n<ul>\n<li>BMS\u2019 revenue growth has been much better, with a <strong>23.7%<\/strong> average annual growth rate in the last three years, compared to <strong>5.1%<\/strong> for J&amp;J.<\/li>\n<li>While J&amp;J\u2019s medical devices business faced headwinds in 2020 due to the pandemic\u2019s impact, it rebounded in 2021. The pharmaceuticals segment saw a 14% rise in 2021 sales, and the medical devices segment sales were up 18%.<\/li>\n<li>BMS\u2019 revenue growth was bolstered by its Celgene<fbs-ticker data-name=\"CELG\" data-href=\"https:\/\/www.forbes.com\/companies\/celgene\" data-type=\"stock\"><br \/>\n   CELG<br \/>\n  <\/fbs-ticker> acquisition in 2019.<\/li>\n<li>If we look at the last twelve-month period, J&amp;J has fared slightly better, with sales growth of 1.2% vs. -0.5% for BMS.<\/li>\n<li>The growth for J&amp;J\u2019s medical devices and pharmaceuticals businesses slowed to 1% each in 2022. This can partly be attributed to lower contribution from the Covid-19 vaccine and falling sales for Remicade, which now faces biosimilar competition.<\/li>\n<li>Although BMS has benefited from market share gains for some of its drugs, including its anticoagulant \u2013 Eliquis &#8211; the company faces biosimilar competition for its top-selling drug \u2013 Revlimid.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/JNJ\/no-login-required\/POMKMcyH\/Johnson-Johnson-JNJ-Revenue-Comparison?fromforbesandarticle=trefis230516\">Johnson &amp; Johnson Revenue Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/no-login-required\/VkU8Ddc9\/Bristol-Myers-Squibb-BMY-Revenue-Comparison?fromforbesandarticle=trefis230516\">Bristol Myers Squibb Revenue Comparison<\/strong> dashboards provide more insight into the companies\u2019 sales.<\/li>\n<li>Looking forward, BMS\u2019 revenue is expected to grow faster than J&amp;J\u2019s over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of 3% for J&amp;J, compared to a 10% CAGR for BMS, based on Trefis Machine Learning analysis.<\/li>\n<li>J&amp;J\u2019s pharmaceuticals business will likely benefit from market share gains for its cancer drug \u2013 Darzalex \u2013 and immunology drugs, Erleada and Tremfya. The company is currently in the process of spinning off its consumer healthcare business as a separately traded company \u2013 Kenvue \u2013 which has already filed for an IPO. The company completed the acquisition of heart pump maker \u2013 Abiomed<fbs-ticker data-name=\"ABMD\" data-href=\"https:\/\/www.forbes.com\/companies\/abiomed\" data-type=\"stock\"><br \/>\n   ABMD<br \/>\n  <\/fbs-ticker> \u2013 last year, and it is expected to aid the top-line growth of its MedTech segment.<\/li>\n<li>For BMS, its Revlimid sales declined a significant 32% y-o-y to $2.3 billion in 2022. However, Opdivo sales were up 11%, and some of its newly approved drugs, including Abecma, Zeposia, Reblozyl, and Breyanzi, were up between 30% and 80%. Most of these drugs are potentially blockbuster drugs, and as they gain market share, their sales growth will likely more than offset the decline from Revlimid.<\/li>\n<li>Note that we have different methodologies for companies negatively impacted by Covid and those not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to predict recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months.<\/li>\n<\/ul>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p><strong>2. J&amp;J Is More Profitable <\/strong><\/p>\n<ul>\n<li>J&amp;J\u2019s operating margin has risen slightly from <strong>24.5%<\/strong> in 2019 to <strong>24.9%<\/strong> in 2022, while BMS\u2019 operating margin declined from <strong>22.6%<\/strong> to <strong>18.0%<\/strong> over this period.<\/li>\n<li>Looking at the last twelve-month period, J&amp;J\u2019s operating margin of <strong>25.4%<\/strong> fares better than <strong>19.7%<\/strong> for BMS.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/JNJ\/no-login-required\/AAPpYe7c\/Johnson-Johnson-JNJ-Operating-Income-Comparison?fromforbesandarticle=trefis230516\">Johnson &amp; Johnson Operating Income Comparison<\/strong><strong> <\/strong>and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/no-login-required\/RUrivPcZ\/Bristol-Myers-Squibb-BMY-Operating-Income-Comparison?fromforbesandarticle=trefis230516\">Bristol Myers Squibb Operating Income Comparison<\/strong> dashboards have more details.<\/li>\n<li>BMS\u2019 free cash flow margin of <strong>28.3%<\/strong> is higher than <strong>22.3%<\/strong> for J&amp;J.<\/li>\n<li>Looking at financial risk, J&amp;J fares better with its <strong>9.6%<\/strong> debt as a percentage of equity lower than <strong>27.5%<\/strong> for BMS and its <strong>12.6%<\/strong> cash as a percentage of assets higher than <strong>9.6% <\/strong>for the latter, implying that J&amp;J has a better debt position and more cash cushion.<\/li>\n<\/ul>\n<p><strong>3. The Net of It All<\/strong><\/p>\n<ul>\n<li>We see that BMS has demonstrated better revenue growth and is available at a comparatively lower valuation multiple. On the other hand, J&amp;J is more profitable and has a better debt position and cash cushion, and this also explains its higher P\/S multiple compared to BMS.<\/li>\n<li>Now, looking at prospects, using P\/S as a base, due to high fluctuations in P\/E and P\/EBIT, we believe BMS is the better choice of the two, given its lower valuation and better prospects.<\/li>\n<li>If we compare the current valuation multiples to the historical averages, BMS fares better, with its stock currently trading at <strong>3.1x<\/strong> trailing revenues vs. the last five-year average of <strong>4.5x. <\/strong>In contrast, JNJ stock trades at <strong>4.4x<\/strong> trailing revenues vs. the last five-year average of <strong>4.9x<\/strong>.<\/li>\n<li>Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/JNJ\/no-login-required\/DxXtClUH\/Johnson-Johnson-JNJ-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230516\">Johnson &amp; Johnson Valuation Ratios Comparison<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/no-login-required\/LrPexLoV\/Bristol-Myers-Squibb-BMY-Valuation-Ratios-Comparison?fromforbesandarticle=trefis230516\">Bristol Myers Squibb Valuation Ratios Comparison<\/strong> have more details.<\/li>\n<li>The table below summarizes our revenue and return expectations for J&amp;J and BMS over the next three years and points to an expected return of <strong>44%<\/strong> for BMS over this period vs. a <strong>10%<\/strong> expected return for J&amp;J, based on Trefis Machine Learning analysis \u2013 <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/JNJ\/no-login-required\/snZKa0ew\/Johnson-Johnson-vs-Bristol-Myers-Squibb-With-Return-Forecast-Of-44-Bristol-Myers-Squibb-Is-A-Better-Bet?fromforbesandarticle=trefis230516\">Johnson &amp; Johnson vs. Bristol Myers Squibb<\/strong> \u2013 which also provides more details on how we arrive at these numbers.<\/li>\n<\/ul>\n<p>While BMY may outperform JNJ in the next three years, it is helpful to see how <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/JNJ\/topic\/peer-comparisons\">Johnson &amp; Johnson\u2019s Peers<\/strong> fare on metrics that matter. You will find other valuable comparisons for companies across industries at <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/topic\/peer-comparisons\">Peer Comparisons<\/strong><strong>.<\/strong><\/p>\n<p>Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you\u2019ll be surprised at how counter-intuitive the stock valuation is for<strong> <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/AMED\/no-login-required\/HSffy3Lj\/Amedisys-vs-Amerco-AMED-stock-s-significantly-higher-valuation-vs-UHAL-appears-counterintuitive?fromforbesandarticle=trefis230516\">Amedisys vs. Amerco<\/strong>.<\/p>\n<p>With higher inflation and the Fed raising interest rates, JNJ has seen a 10% fall this year. Can it drop more? See how low Johnson &amp; Johnson stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.What if you\u2019re looking for a more balanced portfolio instead? Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/THEMES\/no-login-required\/ixlFNWUX\/High-Quality-Portfolio-with-175-Return-Since-2016-vs-50-for-SPY-30-Limit-Version-?fromforbesandarticle=trefis230516\">high-quality portfolio<\/strong> and <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG\/Multi-Strategy-Portfolio-262-Return-Since-2016-vs-102-for-S-P-500?fromforbesandarticle=trefis230516\">multi-strategy portfolio<\/strong> have beaten the market consistently since the end of 2016.<\/p>\n<p>Invest with <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG?fromforbes\">Market Beating Portfolios<\/strong><\/p>\n<p>See all <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/price-estimates?fromforbes\">Price Estimates<\/strong><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2023\/05\/17\/which-pharmaceuticals-stock-is-a-better-pick-johnson--johnson-or-eliquis-maker\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson &amp; Johnson (NYSE: JNJ). J&amp;J trades at a higher valuation of 4.4x trailing revenues, compared to 3.1x for BMS, and this valuation gap will likely narrow over the coming years in favor of BMS, in our view. While [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9878,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-9877","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Johnson &amp; Johnson Or Eliquis\u2019 Maker? | iFintechWorld<\/title>\n<meta name=\"description\" content=\"We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson &amp; Johnson (NYSE: JNJ). J&amp;J trades at a higher\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=9877\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Johnson &amp; Johnson Or Eliquis\u2019 Maker? | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson &amp; Johnson (NYSE: JNJ). J&amp;J trades at a higher\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=9877\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-17T12:10:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-17T12:10:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/05\/1684325414_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=9877#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=9877\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Johnson &#038; Johnson Or Eliquis\u2019 Maker?\",\"datePublished\":\"2023-05-17T12:10:14+00:00\",\"dateModified\":\"2023-05-17T12:10:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=9877\"},\"wordCount\":1170,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=9877#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=9877\",\"url\":\"https:\/\/ifintechworld.com\/?p=9877\",\"name\":\"Johnson & Johnson Or Eliquis\u2019 Maker? | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-05-17T12:10:14+00:00\",\"dateModified\":\"2023-05-17T12:10:15+00:00\",\"description\":\"We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson &amp; Johnson (NYSE: JNJ). J&amp;J trades at a higher\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=9877#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=9877\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=9877#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Johnson &#038; Johnson Or Eliquis\u2019 Maker?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Johnson & Johnson Or Eliquis\u2019 Maker? | iFintechWorld","description":"We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson &amp; Johnson (NYSE: JNJ). J&amp;J trades at a higher","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=9877","og_locale":"en_US","og_type":"article","og_title":"Johnson & Johnson Or Eliquis\u2019 Maker? | iFintechWorld","og_description":"We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson &amp; Johnson (NYSE: JNJ). J&amp;J trades at a higher","og_url":"https:\/\/ifintechworld.com\/?p=9877","og_site_name":"iFintechWorld","article_published_time":"2023-05-17T12:10:14+00:00","article_modified_time":"2023-05-17T12:10:15+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/05\/1684325414_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=9877#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=9877"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Johnson &#038; Johnson Or Eliquis\u2019 Maker?","datePublished":"2023-05-17T12:10:14+00:00","dateModified":"2023-05-17T12:10:15+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=9877"},"wordCount":1170,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=9877#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=9877","url":"https:\/\/ifintechworld.com\/?p=9877","name":"Johnson & Johnson Or Eliquis\u2019 Maker? | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-05-17T12:10:14+00:00","dateModified":"2023-05-17T12:10:15+00:00","description":"We believe Bristol Myers Squibb stock (NYSE: BMY) is a better pick than its industry peer, Johnson &amp; Johnson (NYSE: JNJ). J&amp;J trades at a higher","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=9877#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=9877"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=9877#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Johnson &#038; Johnson Or Eliquis\u2019 Maker?"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/9877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9877"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/9877\/revisions"}],"predecessor-version":[{"id":9879,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/9877\/revisions\/9879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/9878"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}